Net product sales in SCD market: Oxbryta & Adakveo

Last Update: Aug 8, 2022

in millions, $, exc. Rx Q419 Q120 Q220 Q320 Q420 Q121 Q221 Q321 Q421 Q122 Q222 FY 2019 2020 2021
Oxbryta New Oxbryta Prescriptions 350 1,650 1,000 1,000 950 950 925 850 800 1,200 350 4,600 3,525
Total Oxbryta Prescriptions 350 1,650 2,650 3,100 4,050 5,000 5,925 6,775 7,575 8,775 350 11,450 25,275
Global Oxbryta Revenue 2 14 32 37 41 39 48 52 56 55 72 2 124 195
Adakveo Global Adakveo Revenue - 15 21 35 34 37 42 42 43 44 49 - 105 164
SCD prevalence - US 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000 95,000
SCD prevalence - EU 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000 60,000
Net product sales of Oxbryta & Adakveo by quarter and year. Oxbryta U.S. list price: $125,000/yr (WAC). Adakveo U.S list price: $85,000-115,000/yr (WAC). Notes: Oxbryta and Adakveo labels do not overlap completely. SCD prevalence numbers are approximations. Oxbryta was launched in Germany mid-May. Adakveo received NICE recommendation (UK) in October 2021.


Have feedback? Tweet or DM me @blackseedbio on Twitter, or contact me here.

If you want to get notified when updates are available, please consider subscribing.

SUBSCRIBE